Detalles de la búsqueda
1.
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.
Oncologist
; 28(9): 812-822, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37011230
2.
Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study.
Cancer
; 128(2): 311-316, 2022 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34614198
3.
Oncology education for family medicine residents: a national needs assessment survey.
BMC Med Educ
; 20(1): 283, 2020 Aug 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32854702
4.
Machine learning for prediction of cutaneous adverse events in patients receiving anti-PD-1 immunotherapy.
J Am Acad Dermatol
; 84(1): 183-185, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32334053
5.
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
JAMA Netw Open
; 7(1): e2352302, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236598
6.
Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
BMJ Open
; 13(10): e066378, 2023 10 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37844982
7.
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
JTO Clin Res Rep
; 4(4): 100482, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37090101
8.
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
Clin Lung Cancer
; 24(3): e152-e159, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36774234
9.
Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab.
Curr Oncol
; 29(10): 7695-7704, 2022 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36290885
10.
Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?
JCO Oncol Pract
; 18(7): e1164-e1169, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35696634
11.
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
JAMA Netw Open
; 5(12): e2245596, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36480204
12.
Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.
J Cancer Policy
; 30: 100311, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35559802
13.
The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma.
Curr Oncol
; 28(6): 4542-4551, 2021 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34898559
14.
Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
JAMA Intern Med
; 181(4): 499-508, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33616606
15.
Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets.
J Cancer Policy
; 28: 100283, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35559912
16.
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Cancer Med
; 10(8): 2618-2626, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724676
17.
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database.
Curr Oncol
; 28(5): 4213-4222, 2021 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34677275
18.
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Eur J Cancer
; 151: 115-125, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33975059
19.
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Cancer Med
; 9(13): 4640-4647, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32378799
20.
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.
Cancers (Basel)
; 11(11)2019 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31684111